Symbolbild · KI-generiert
REGENXBIO Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
REGENXBIO is a biotechnology company developing gene therapies based on its NAV® technology platform, a library of patented adeno-associated viruses (AAV). The company licences its vectors to other gene therapy firms and develops its own programmes for rare retinal diseases and other genetically determined conditions. REGENXBIO holds extensive patent rights covering several clinically relevant AAV serotypes.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| REGENXBIO Inc. | RGNX | NASDAQ | 501 Mio. USD |
| Ginkgo Bioworks Holdings, Inc. | DNA | NYSE | 503 Mio. USD |
| Eikon Therapeutics, Inc. | EIKN | NASDAQ | 499 Mio. USD |
| ARS Pharmaceuticals, Inc. | SPRY | NASDAQ | 509 Mio. USD |
| Verastem, Inc. | VSTM | NASDAQ | 510 Mio. USD |
| Silence Therapeutics Plc American Depository Share | SLN | NASDAQ | 491 Mio. USD |
| Zura Bio Limited | ZURA | NASDAQ | 516 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.